Evidence map›Paper›PMID 42471331›Full record

ArticleBlood cancer journal2026

Detailed immunophenotypic and genetic characterization of bone marrow clonal plasma cells and B-cells in early-stage monoclonal gammopathies.

Oihane Pérez-Escurza, P Martijn Kolijn, Jón Þórir Óskarsson, María González-González, María Jara-Acevedo, Julio Del Pozo, Quentin Lécrevisse, Juan Flores-Montero, Luzalba Sanoja-Flores, Silvia Martín and 11 more

Abstract read
In one paragraph

Article in Blood cancer journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Oihane Pérez-EscurzaTranslational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC-USAL); Cytometry Service (NUCLEUS); Department of Medicine, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.ORCID http://orcid.org/0000-0002-6966-4337
P Martijn KolijnLaboratory Medical Immunology, Department of Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Jón Þórir ÓskarssonFaculty of Medicine, University of Iceland, Reykjavík, Iceland.ORCID http://orcid.org/0000-0002-9201-1166
María González-GonzálezTranslational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC-USAL); Cytometry Service (NUCLEUS); Department of Medicine, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
María Jara-AcevedoTranslational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC-USAL); Cytometry Service (NUCLEUS); Department of Medicine, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Julio Del PozoTranslational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC-USAL); Cytometry Service (NUCLEUS); Department of Medicine, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Quentin LécrevisseTranslational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC-USAL); Cytometry Service (NUCLEUS); Department of Medicine, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.ORCID http://orcid.org/0000-0001-8715-5846
Juan Flores-MonteroTranslational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC-USAL); Cytometry Service (NUCLEUS); Department of Medicine, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.ORCID http://orcid.org/0000-0002-1119-4387
Luzalba Sanoja-FloresThe Binding Site Group, Birmingham, UK.
Silvia MartínTranslational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC-USAL); Cytometry Service (NUCLEUS); Department of Medicine, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
Elín Ruth ReedFaculty of Medicine, University of Iceland, Reykjavík, Iceland.
Stephen HardingThe Binding Site Group, Birmingham, UK.
Sigrún ThorsteinsdottirFaculty of Medicine, University of Iceland, Reykjavík, Iceland.ORCID http://orcid.org/0000-0001-5017-3530
Sæmundur RögnvaldssonFaculty of Medicine, University of Iceland, Reykjavík, Iceland.
Thorvardur Jon LoveFaculty of Medicine, University of Iceland, Reykjavík, Iceland.
Brian DurieDepartment of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Anton W LangerakLaboratory Medical Immunology, Department of Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0002-2078-3220
Sigurdur Yngvi KristinssonFaculty of Medicine, University of Iceland, Reykjavík, Iceland.ORCID http://orcid.org/0000-0002-4964-7476
Alberto OrfaoTranslational and Clinical Research Program, Cancer Research Center (IBMCC, CSIC-USAL); Cytometry Service (NUCLEUS); Department of Medicine, University of Salamanca (Universidad de Salamanca), Salamanca, Spain. orfao@usal.es.ORCID http://orcid.org/0000-0002-0007-7230
iStopMM
ECRIN-M3

Funding

Consejería de Educación, Junta de Castilla y León (Consejería de Educación de la Junta de Castilla y León) Orden EDU/601/2020
6 · The paper itself

Abstract

Monoclonal gammopathy (MG) of undetermined significance (MGUS) is the earliest and most prevalent stage of MG that may progress to symptomatic multiple myeloma (MM) or Waldenström's macroglobulinemia (WM) through intermediate smoldering forms of both diseases. We used next-generation flow cytometry (NGF) to identify and purify bone marrow (BM) clonal plasma cells (cPC) and B-cells/lymphoplasmacytic cells (cB-cells) from 25 asymptomatic individuals with MG diagnosed within the population-based iStopMM screening program for further molecular analysis by next-generation sequencing (NGS). IgM-MGUS cases consistently exhibited WM-like phenotypes by NGF, and MYD88 p.L265P and/or CXCR4 mutations in the coexisting cPC and cB-cells. Conversely, cPC from non-IgM MGUS and smoldering MM (SMM) displayed a MM-like phenotype associated with genetic drivers -i.e., t(11;14)-, frequently coexisting with genetically unrelated cB-cells. Interestingly, recurrent RUNX1 single nucleotide variants were detected in cPC, but not coexisting cB-cells, from WM-like cases, suggesting a role for RUNX1 in PC differentiation. In summary, NGF enabled detailed immunophenotypic characterization of BM cPC and cB-cell populations in all cases analyzed, subdivided in IgM vs non-IgM cases with WM-like or MM-like phenotypic and genetic profiles, respectively. These findings underscore the potential contribution of NGF and NGS for accurate classification or early-stage disease, beyond conventional criteria.

Indexed as

B-LymphocytesBone MarrowBone Marrow CellsMonoclonal Gammopathy of Undetermined SignificanceParaproteinemiasPlasma CellsAgedFemaleHumansImmunophenotypingMaleMiddle AgedMutationWaldenstrom Macroglobulinemia

Identifiers

PMID42471331
PMCPMC13661609

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.